source
- City Therapeutics completes $200 million IPO, earmarks funds for RNAi therapiesCity Therapeutics, based in Cambridge, Massachusetts, launched an IPO raising $200 million, exceeding its original target of 9.7 million shares at $17-$19 per share. The company sold 11.1 million…
- City Therapeutics raises $200M in IPO to fund thromboembolic disease pipelineCity Therapeutics, an RNA interference biotech focused on thromboembolic diseases, completed an initial public offering that raised $200 million. The company sold about 11 million shares at $18 ea…